Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus
Diabetes mellitus is the most common metabolic disorder worldwide. Some herbs are traditionally used in treatment of type 2 diabetes mellitus (T2DM). Urtica Dioica (UD) or stinging nettle is traditionally used in Morocco, Turkey, Brasil, Jordan and with much frequency in northern Iran.
Studies on animal models along with in vitro studies has shown hypoglycemic effect for aqueous extract of UD.
This study aimed to investigate hypoglycemic effects of UD tea bags in patients with T2DM on glycemic control, insulin sensitivity, along with its effects on lipid profile (LP), blood pressure (BP), liver, and kidney function.
|Study Design:||Allocation: Randomized
Intervention Model: Factorial Assignment
Primary Purpose: Treatment
|Official Title:||Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus|
- Fasting blood glucose every two weeks.
- Post prandial blood glucose every two weeks.
- Fasting insulin every two weeks.
- Insulin sensitivity as Quantitative Insulin Sensitivity Check Index (QUIKI) every two weeks.
- C-Peptide every two weeks.
- HBA1C every two weeks.
- Serum lipids every two weeks.
- Liver enzymes (ALT, AST) every two weeks.
- GFR every two weeks.
- Blood pressure every two weeks.
|Study Start Date:||January 2007|
|Study Completion Date:||April 2007|
The study will be performed under randomized, double-blind, placebo controlled, and case-control design. The object of this study is patients with T2DM. Patients are randomly assigned to start with placebo tea bags (3 tea bags as 2-gram tea bag steamed in boiling water for 20 minutes: mixture of bran powder which is already boiled in water twice plus spinach powder) in control groups and UD tea bags (3 tea bags as 2-gram tea bag steamed in boiling water for 20 minutes) in patients with T2DM for two months. Every two weeks, fasting glucose, postprandial glucose after a standard breakfast, serum insulin, lipids, alanine amino transferase (ALT), aspartate amino transferase (AST), creatinine (to calculate GFR), along with blood pressure will be measured.
To the best of our knowledge, this is the first Randomized Clinical Trial.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00422357
|Iran, Islamic Republic of|
|Primary Health Care Office|
|Mahmood-Abaad, Mazandaran, Iran, Islamic Republic of|
|Study Chair:||Reza Rastmanesh, Ph.D.||Shahid Beheshti University of Medical Sciences|
|Study Director:||Navid Saadat, MD||Shaheed Beheshti Medical Univrsity|